These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38698025)

  • 61. Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study.
    Aimo A; Teresi L; Castiglione V; Picerni AL; Niccolai M; Severino S; Agazio A; Carnevale Baraglia A; Obici L; Palladini G; Ponti L; Argirò A; Cappelli F; Perfetto F; Serenelli M; Trimarchi G; Licordari R; Di Bella G; Chubuchna O; Quattrone F; Nuti S; De Rosis S; Passino C; Rapezzi C; Merlini G; Emdin M; Vergaro G
    Amyloid; 2024 Mar; 31(1):52-61. PubMed ID: 37668548
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.
    Carroll A; Dyck PJ; de Carvalho M; Kennerson M; Reilly MM; Kiernan MC; Vucic S
    J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):668-678. PubMed ID: 35256455
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [ANMCO Position paper: Amyloidosis for the clinical cardiologist. A "clinical primer" from the ANMCO Rare Disease Working Group].
    Chimenti C; Grego S; Di Fusco S; De Luca L; Caldarola P; Cannillo M; Cipriani M; Di Lenarda A; Donato D; Leone S; Limongelli G; Navazio A; Riccio C; Valente S; Gulizia MM; Gabrielli D; Oliva F; Colivicchi F
    G Ital Cardiol (Rome); 2023 Feb; 24(2):127-135. PubMed ID: 36735312
    [TBL] [Abstract][Full Text] [Related]  

  • 64. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis.
    Coelho T; Maurer MS; Suhr OB
    Curr Med Res Opin; 2013 Jan; 29(1):63-76. PubMed ID: 23193944
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
    Rapezzi C; Elliott P; Damy T; Nativi-Nicolau J; Berk JL; Velazquez EJ; Boman K; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
    JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging.
    Narotsky DL; Castano A; Weinsaft JW; Bokhari S; Maurer MS
    Can J Cardiol; 2016 Sep; 32(9):1166.e1-1166.e10. PubMed ID: 27568874
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Merkel M; Danese D; Chen C; Wang J; Wu A; Yang H; Lin H
    Expert Opin Pharmacother; 2023; 24(10):1205-1214. PubMed ID: 37219406
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies.
    Mariotto S; Farinazzo A; Magliozzi R; Alberti D; Monaco S; Ferrari S
    J Peripher Nerv Syst; 2018 Sep; 23(3):174-177. PubMed ID: 29974556
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Increased thickness of lumbar spine ligamentum flavum in wild-type transthyretin amyloidosis.
    George KM; Hernandez NS; Breton J; Cooper B; Dowd RS; Nail J; Yu A; Mastroianni M; Wang A; Godara A; Zhang D; Arkun K; Patel AR; Varga C; Soto O; Kryzanski J; Comenzo R; Riesenburger R
    J Clin Neurosci; 2021 Feb; 84():33-37. PubMed ID: 33485595
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Transthyretin amyloidosis: an under-recognized neuropathy and cardiomyopathy.
    Galant NJ; Westermark P; Higaki JN; Chakrabartty A
    Clin Sci (Lond); 2017 Mar; 131(5):395-409. PubMed ID: 28213611
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Association between spinal stenosis and wild-type ATTR amyloidosis.
    Godara A; Riesenburger RI; Zhang DX; Varga C; Fogaren T; Siddiqui NS; Yu A; Wang A; Mastroianni M; Dowd R; Nail TJ; McPhail ED; Kurtin PJ; Theis JD; Toskic D; Arkun K; Pilichowska M; Kryzanski J; Patel AR; Comenzo R
    Amyloid; 2021 Dec; 28(4):226-233. PubMed ID: 34263670
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phenotypic characteristics of F64L, I68L, I107V, and S77Y ATTRv genotypes from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
    Gentile L; Diemberger I; Plante-Bordeneuve V; Mazzeo A; Dori A; Luigetti M; Di Paolantonio A; Dispenzieri A; Grogan M; Waddington Cruz M; Adams D; Inamo J; Kristen AV; Lino Cirami C; Chapman D; Gupta P; Glass O; Amass L
    PLoS One; 2024; 19(1):e0292435. PubMed ID: 38241252
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
    Campbell CM; LoRusso S; Dispenzieri A; Kristen AV; Maurer MS; Rapezzi C; Lairez O; Drachman B; Garcia-Pavia P; Grogan M; Chapman D; Amass L;
    Cardiol Ther; 2022 Sep; 11(3):393-405. PubMed ID: 35583798
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prevalence of transthyretin-related amyloidosis in Tuscany: Data from the regional population-based registry.
    Cappelli F; Del Franco A; Vergaro G; Mazzoni C; Argirò A; Pieroni M; Giacomin E; Poli S; Allinovi M; Olivotto I; Pieroni F; Scaletti C; Emdin M; Perfetto F
    Int J Cardiol; 2023 Jul; 382():87-90. PubMed ID: 37004943
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cardiac Transthyretin Amyloidosis: A Nuclear Medicine Leading Role. Situation in a Spanish Center and "State of the Art" in Nuclear Medicine.
    Roteta Unceta Barrenechea A; Aibar Arregui MA; Nogueira Souto D; Melero Polo J; Moreno Gázquez I; Tardin Cardoso L; Saker Diffalah Y; Andrés Gracia A
    Clin Nucl Med; 2021 Jun; 46(6):456-464. PubMed ID: 33630805
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths.
    González-López E; Gagliardi C; Dominguez F; Quarta CC; de Haro-Del Moral FJ; Milandri A; Salas C; Cinelli M; Cobo-Marcos M; Lorenzini M; Lara-Pezzi E; Foffi S; Alonso-Pulpon L; Rapezzi C; Garcia-Pavia P
    Eur Heart J; 2017 Jun; 38(24):1895-1904. PubMed ID: 28329248
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Neurological manifestations of ATTR amyloidosis].
    Pernice HF; Hahn K
    Inn Med (Heidelb); 2023 Sep; 64(9):848-854. PubMed ID: 37555967
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Outcomes After Cardiac Transplant for Wild Type Transthyretin Amyloidosis.
    Rosenbaum AN; AbouEzzeddine OF; Grogan M; Dispenzieri A; Kushwaha S; Clavell A; Daly RC; Edwards BS
    Transplantation; 2018 Nov; 102(11):1909-1913. PubMed ID: 29677073
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Sex-related differences in the clinical characteristics of wild-type transthyretin amyloidosis cardiomyopathy.
    Takashio S; Yamada T; Nishi M; Morioka M; Fujiyama A; Nakashima N; Hirakawa K; Hanatani S; Usuku H; Yamamoto E; Ueda M; Matsushita K; Tsujita K
    J Cardiol; 2022 Jan; 79(1):50-57. PubMed ID: 34756766
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prevalence of Monoclonal Gammopathy in Wild-Type Transthyretin Amyloidosis.
    Geller HI; Singh A; Mirto TM; Padera R; Mitchell R; Laubach JP; Falk RH
    Mayo Clin Proc; 2017 Dec; 92(12):1800-1805. PubMed ID: 29202938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.